The Globe and Mail reports in its Wednesday, June 11, edition that National Bank Financial analyst John Shao rates Vitalhub "outperform" in new coverage. The Globe's David Leeder writes in the Eye On Equities column that Mr. Shao set a share target of $14. Analysts on average target the shares at $13.78. Mr. Shao sees Vitalhub currently at "a convenient spot to harvest future opportunities by leveraging its already well-oiled M&A engine." Mr. Shao says in a note: "On one hand, the company has already passed the early stage of a roll-up story, and its ability to deploy capital has already been proven, leading to lower execution risk. On the other hand, the company's scale is not too big to become a victim of the law of large numbers (e.g., smaller deals that don't move the needle). As such, executing smaller deals (which tend to carry lower valuations and a high ROIC) will remain Vitalhub's bread and butter, further reducing that execution risk. ... What sets Vitalhub apart from other Canadian tech roll-ups is its double-digit organic growth at an average of 16 per cent since 2022. This robust growth underscores Vitalhub's strong market position and highlights its ability to identify high-growth targets."